Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Bao Pharmaceuticals CoHKSE:02659 +0.25%9 PB Ratio is 2.95 as of Aug. 27, 2026, which is 78% below its 10-year median of 13.68. GuruFocus rates HKSE:02659 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 1,212 Biotechnology companies, Shanghai Bao Pharmaceuticals Co ranks better than 50.25% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Shanghai Bao Pharmaceuticals Co PB Ratio Related Terms
Shanghai Bao Pharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co PB Ratio Chart
Shanghai Bao Pharmaceuticals Co Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
14.37
Shanghai Bao Pharmaceuticals Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PB Ratio
0.00
0.00
0.00
0.00
14.37
HKSE:02659 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Shanghai Bao Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Bao Pharmaceuticals Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Bao Pharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Bao Pharmaceuticals Co's PB Ratio falls into.
Shanghai Bao Pharmaceuticals Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a PB Ratio of 2.95 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. This is 78% below median its historical median of 13.68. Over the past decade, Shanghai Bao Pharmaceuticals Co's PB Ratio has ranged from 2.90 to 33.79. According to the industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #603 out of 1212 companies in the Biotechnology industry, placing it in the top 49.8%.
Is Shanghai Bao Pharmaceuticals Co's PB Ratio too high?
Shanghai Bao Pharmaceuticals Co's current PB Ratio of 2.95 is 78% below median its 10-year median of 13.68. Over the past 10 years, this metric has ranged from a low of 2.90 to a high of 33.79. The Biotechnology industry median PB Ratio is 2.98. Shanghai Bao Pharmaceuticals Co's value of 2.95 is 0.8% below this industry median. Based on the distribution chart, Shanghai Bao Pharmaceuticals Co ranks #603 out of 1212 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #603 out of 1212 companies for PB Ratio. This puts Shanghai Bao Pharmaceuticals Co in the upper half of its industry. The industry median PB Ratio is 2.98. Shanghai Bao Pharmaceuticals Co's value of 2.95 is 0.8% below this benchmark. Historically, Shanghai Bao Pharmaceuticals Co's own PB Ratio has ranged from 2.90 to 33.79 over the past decade. While the company's 10-year median is 13.68 vs. the industry median of 2.98, Shanghai Bao Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.98, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Bao Pharmaceuticals Co's current PB Ratio of 2.95 is 0.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Bao Pharmaceuticals Co's current PB Ratio is 2.95, which is 78% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current PB Ratio of 2.95. The current PB Ratio is 2.95, which is 78% below median its 10-year median of 13.68 and 0.8% below the Biotechnology industry median of 2.98. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current PB Ratio is 2.95 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score
Get the complete analysis for HKSE:02659
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02659 has been successfully added to your 
